Christopher DelOrefice's most recent trade in Ulta Beauty Inc was a trade of 14,363 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ulta Beauty | Christopher J. DelOrefice | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 14,363 | 14,363 | - | - | Stock Option (right to buy) | |
| Ulta Beauty | Christopher J. DelOrefice | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 4,219 | 9,693 (0%) | 0% | 0 | Common Stock | |
| Ulta Beauty | Christopher J. DelOrefice | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 3,649 | 5,474 (0%) | 0% | 0 | Common Stock | |
| Ulta Beauty | Christopher J. DelOrefice | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 1,825 | 1,825 (0%) | 0% | 0 | Common Stock | |
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2025 | 6,006 | 27,227 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2025 | 4,245 | 22,982 (0%) | 0% | 0 | Common Stock | ||
| ResMed | Christopher J. DelOrefice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2025 | 1,073 | 2,423 (0%) | 0% | 0 | ResMed Common Stock | |
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 01 Sep 2025 | 278 | 21,221 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2024 | 19,138 | 19,138 | - | - | Stock Appreciation Rights | ||
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2024 | 9,015 | 26,691 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2024 | 5,192 | 21,499 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher J. DelOrefice | EVP & Chief Financial Officer | 26 Nov 2024 | 4,884 | 17,676 (0%) | 0% | 0 | Common Stock | ||
| ResMed | Christopher DelOrefice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 1,350 (0%) | 0% | 0 | ResMed Common Stock | |
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 07 Sep 2024 | 466 | 12,792 (0%) | 0% | 0 | Common Stock | ||
| ResMed | Christopher DelOrefice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 267 | 267 (0%) | 0% | 0 | ResMed Common Stock | |
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 01 Sep 2024 | 254 | 13,258 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2023 | 18,425 | 18,425 | - | - | Stock Appreciation Rights | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2023 | 3,325 | 14,324 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2023 | 812 | 13,512 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 07 Sep 2023 | 601 | 10,999 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 01 Sep 2023 | 353 | 11,600 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2022 | 18,658 | 18,658 | - | - | Stock Appreciation Rights | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2022 | 3,087 | 12,222 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & Chief Financial Officer | 26 Nov 2022 | 269 | 11,953 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & CFO | 07 Sep 2022 | 506 | 9,135 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & CFO | 01 Sep 2022 | 2,674 | 9,641 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & CFO | 26 Nov 2021 | 18,638 | 18,638 | - | - | Stock Appreciation Rights | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & CFO | 26 Nov 2021 | 2,608 | 6,967 (0%) | 0% | 0 | Common Stock | ||
| Becton, Dickinson and Co. | Christopher DelOrefice | EVP & CFO | 07 Sep 2021 | 4,359 | 4,359 (0%) | 0% | 0 | Common Stock |